Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Novartis provided an update on its delpacibart etedesiran Phase III HARBOR study in myotonic dystrophy type 1 (DM1), saying the neuromuscular drug candidate missed its late-stage trial goal.
NOVARTIS AG BX:NOT
Novartis provided an update on its Phase III HARBOR study of delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1).